This study aims to find the best dose and side effects of two medicines, venetoclax and tocilizumab, for people with a specific type of multiple myeloma, a blood cancer. Venetoclax helps stop cancer cell growth by blocking a protein called Bcl-2. Tocilizumab is a monoclonal antibody, meaning it's a special protein made to target cancer cells, and it's used to treat immune-related side effects. Together, these medicines might kill more cancer cells. **Key Points:** - **Study Duration:** Treatment cycles last 21 days and repeat unless there's disease progression or unacceptable side effects. - **Eligibility:** Requires previous treatment, positive test for a specific genetic change (t(11;14)), and recovery from transplant if applicable. - **Follow-up:** After treatment, patients are monitored for 4 weeks and then every 6 months. Patients must be 18 or older, have sufficient blood counts, and meet other health criteria. The study excludes those with certain infections, other active cancers, or those unable to consent. This is a phase I trial, meaning it's an early-stage study mainly to find safe dosages and check side effects.